- Home
- AIIO vs ADAG Comparison
AIIO vs ADAG Comparison
Compare AIIO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIO | ADAG |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United Arab Emirates | China |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.6M | 90.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIIO | ADAG |
|---|---|---|
| Price | $0.14 | $3.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 10.9M | 248.4K |
| Earning Date | 05-27-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,742,000.00 | $103,204.00 |
| Revenue This Year | N/A | $3,688.61 |
| Revenue Next Year | N/A | $17.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $1.30 |
| 52 Week High | $3.48 | $3.19 |
Technical Indicators
Market Signals| Indicator | AIIO | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 23.85 | N/A |
| Support Level | $0.15 | N/A |
| Resistance Level | $0.20 | N/A |
| Average True Range (ATR) | 0.03 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 2.83 | 0.00 |
Price Performance
Historical ComparisonAbout AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.